KMD Bioscience has been dedicated to antibody research for many years. Antibody affinity is a core parameter that determines the binding activity, potency, and clinical application potential of antibody drugs. Humanized antibodies generated via CDR grafting often suffer from varying degrees of affinity reduction due to conformational changes in antigen binding caused by framework region sequence substitutions. Therefore, directed improvement of antibody affinity through in vitro affinity maturation technologies represents a critical step in the antibody optimization phase.
KMD Bioscience possesses a well-established phage display platform and affinity characterization system, offering one-stop affinity maturation services for antibodies derived from multiple species. We are capable of constructing mutant libraries with a diversity exceeding 1010 independent clones. Through rigorous multi-round screening and identification, most projects achieve an affinity improvement of 1–3 orders of magnitude, reaching nanomolar or even picomolar levels. In parallel, we provide comprehensive support including antibody sequence analysis, soluble expression, affinity and specificity validation, and customized optimization strategies tailored to individual client needs, efficiently supporting early-stage development of antibody therapeutics.
0
